The effects of letrozole on women with endometriosis undergoing ovarian stimulation for in vitro fertilization

References

• Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362:2389–2398.
   PubMed Web of Science ®Google Scholar
• Kitawaki J, Kado N, Ishihara H, et al. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 2002;83:149–155.
   PubMed Web of Science ®Google Scholar
• Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril. 2006;85:1307–1318.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89.
   PubMed Web of Science ®Google Scholar
• Nawathe A, Patwardhan S, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG. 2008;115:818–822.
   PubMed Web of Science ®Google Scholar
• Slopien R, Meczekalski B. Aromatase inhibitors in the treatment of endometriosis. Prz Menopauzalny. 2016;15:43–47.
   PubMedGoogle Scholar
• Yarali H, Esinler I, Polat M, et al. Antagonist/letrozole protocol in poor ovarian responders for intracytoplasmic sperm injection: a comparative study with the microdose flare-up protocol. Fertil Steril. 2009;92:231–235.
   PubMed Web of Science ®Google Scholar
• Lazer T, Dar S, Shlush E, et al. Comparison of IVF outcomes between minimal stimulation and high-dose stimulation for patients with poor ovarian reserve. Int J Reprod Med. 2014;2014:1.
   Google Scholar
• Weil S, Vendola K, Zhou J, et al. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab. 1999;84:2951–2956.
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco JA, Moreno L, Pacheco A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril. 2005;84:82–87.
   PubMed Web of Science ®Google Scholar
• Ozmen B, Sönmezer M, Atabekoglu CS, et al. Use of aromatase inhibitors in poor-responder patients receiving GnRH antagonist protocols. Reprod Biomed Online. 2009;19:478–485.
   PubMed Web of Science ®Google Scholar
• Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril. 2012;98:1363–1369.
   PubMed Web of Science ®Google Scholar
• Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885–3890.
   PubMed Web of Science ®Google Scholar
• Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32:1033–1045.
   PubMed Web of Science ®Google Scholar
• Renier M, Verheyden B, Termote L. An unusual coincidence of endometriosis and ovarian stimulation. Eur J Obstet Gynecol Reprod Biol. 1995;63:187–189.
   PubMed Web of Science ®Google Scholar
• Anaf V, El Nakadi I, Simon P, et al. Sigmoid endometriosis and ovarian stimulation. Hum Reprod. 2000;15:790–794.
   PubMed Web of Science ®Google Scholar
• van der Houwen LE, Schreurs AM, Schats R, et al. Efficacy and safety of intrauterine insemination in patients with moderate-to-severe endometriosis. Reprod Biomed Online. 2014;28:590–598.
   PubMed Web of Science ®Google Scholar
• Remohi J, Ardiles G, Garcia-Velasco JA, et al. Endometrial thickness and serum oestradiol concentrations as predictors of outcome in oocyte donation. Hum Reprod. 1997;12:2271–2276.
   PubMed Web of Science ®Google Scholar
• Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99:1476–1484.
   PubMed Web of Science ®Google Scholar
• Quinn MM, Cakmak H, Letourneau JM, et al. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017;32:568–574.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SK, Lee HJ, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci. 2015;30:290–295.
   PubMed Web of Science ®Google Scholar
• Hu Y, Cortvrindt R, Smitz J. Effects of aromatase inhibition on in vitro follicle and oocyte development analyzed by early preantral mouse follicle culture. Mol Reprod Dev. 2002;61:549–559.
   PubMed Web of Science ®Google Scholar
• Turan V, Bedoschi G, Moy F, et al. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril. 2013;100:1681–1685.e1.
   PubMed Web of Science ®Google Scholar
• Domingo J, Guillén V, Ayllón Y, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97:930–934.
   PubMed Web of Science ®Google Scholar
• Gallos ID, Khairy M, Chu J, et al. Optimal endometrial thickness to maximize live births and minimize pregnancy losses: analysis of 25,767 fresh embryo transfers. Reprod Biomed Online. 2018; 37:542–548.
   PubMed Web of Science ®Google Scholar
• Simon C, Cano F, Valbuena D, et al. Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Hum Reprod. 1995;10:2432–2437.
   PubMed Web of Science ®Google Scholar
• Miller PB, Parnell BA, Bushnell G, et al. Endometrial receptivity defects during IVF cycles with and without letrozole. Hum Reprod. 2012;27:881–888.
   PubMed Web of Science ®Google Scholar
• Lessey BA, Castelbaum AJ, Sawin SW, et al. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metab. 1994;79:643–649.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Justice R, et al. Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval. Oncologist. 2011;16:1762–1770.
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Jwa SC, Kuwahara A, et al. No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod. 2017;32:125–132.
   PubMed Web of Science ®Google Scholar